Clinical trial
A Phase 1 Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT Administered Intrathoracically in Single and Multiple Doses in Patients With Pleurisy
NCT06525272 is registered in ClinicalTrials.gov with Healthgen Biotechnology Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT Administered Intrathoracically in Single and Multiple Doses in Patients With Pleurisy
- Lead sponsor
- Healthgen Biotechnology Corp.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- July 31, 2024
- Completion date
- December 31, 2025
- Enrollment
- 72 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.